Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.54 |
| ▸ | GPR139 | Q6DWJ6 | 15/20 | 0.39 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.34 |
| ▸ | RAF1 | P04049 | 1/20 | 0.33 |
| ▸ | YES1 | P07947 | 1/20 | 0.33 |
| ▸ | BRAF | P15056 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL307295 | 0.91 | TRPV1 (0.66) | TRPV1GPR139ENPP2RAF1YES1 | |
| SCHEMBL1389264 | 0.88 | TRPV1 (0.68) | TRPV1GPR139ENPP2MAPK1 | |
| SCHEMBL1389262 | 0.88 | TRPV1 (0.68) | TRPV1GPR139ENPP2MAPK1 | |
| SCHEMBL307308 | 0.87 | TRPV1 (0.52) | TRPV1GPR139MAPK1 | |
| SCHEMBL309312 | 0.84 | TRPV1 (0.56) | TRPV1GPR139ENPP2 | |
| SCHEMBL309311 | 0.84 | TRPV1 (0.56) | TRPV1GPR139ENPP2 | |
| SCHEMBL306917 | 0.83 | TRPV1 (0.46) | TRPV1GPR139ENPP2RAF1YES1 | |
| SCHEMBL306931 | 0.83 | TRPV1 (0.43) | TRPV1ENPP2MAPK1 | |
| SCHEMBL14292380 | 0.81 | TRPV1 (0.68) | TRPV1GPR139ENPP2MAPK1 | |
| SCHEMBL14291910 | 0.79 | TRPV1 (0.71) | TRPV1GPR139ENPP2MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2051967-B1 | BENZIMIDAZOLE DERIVATIVES USEFUL IN TREATMENT OF VALLINOID RECEPTOR TRPV1 RELATED DISORDERS | NEOMED INST (CA) | 2014-12-31 | — | — | EP | claimed |
| US-8093402-B2 | Benzimidazole derivatives | ASTRAZENECA AB (SE) | 2012-01-10 | — | — | US | claimed |
| US-20110137045-A1 | BENZIMIDAZOLE DERIVATIVES | ASTRAZENECA AB (SE) | 2011-06-09 | — | — | US | claimed |
| EP-2051967-A1 | BENZIMIDAZOLE DERIVATIVES USEFUL IN TREATMENT OF VALLINOID RECEPTOR TRPV1 RELATED DISORDERS | AstraZeneca AB (SE) | 2009-04-29 | — | — | EP | claimed |
| US-20080221188-A1 | New Benzimidazole Derivatives | ASTRAZENECA R&D SODERTALJE (SE) | 2008-09-11 | — | — | US | claimed |
| WO-2008018827-A1 | BENZIMIDAZOLE DERIVATIVES USEFUL IN TREATMENT OF VALLINOID RECEPTOR TRPV1 RELATED DISORDERS | ASTRAZENECA AB (SE) | 2008-02-14 | — | — | WO | claimed |
| US-8093402-B2 | Benzimidazole derivatives | ASTRAZENECA AB (SE) | 2012-01-10 | — | — | US | disclosed |
| US-20110137045-A1 | BENZIMIDAZOLE DERIVATIVES | ASTRAZENECA AB (SE) | 2011-06-09 | — | — | US | disclosed |
| US-7906654-B2 | (S)(-)-2-(7-chloro-6-fluoro-1H-benzimidazol-1-yl)-N-{1-[4-(1-cyano-1-methylethyl)phenyl]ethyl}acetamide; treatment of pain; vanilloid receptor inhibitor; Antagonists maintain analgesic properties, but avoid pungency and neurotoxicity side effects of agonists | ASTRAZENECA AB (SE) | 2011-03-15 | — | — | US | disclosed |
| EP-2051980-A1 | PYRROLOTRIAZINE KINASE INHIBITORS | Brystol-Myers Squibb Company (US) | 2009-04-29 | — | — | EP | disclosed |
| EP-2051967-A1 | BENZIMIDAZOLE DERIVATIVES USEFUL IN TREATMENT OF VALLINOID RECEPTOR TRPV1 RELATED DISORDERS | AstraZeneca AB (SE) | 2009-04-29 | — | — | EP | disclosed |
| US-20080221188-A1 | New Benzimidazole Derivatives | ASTRAZENECA R&D SODERTALJE (SE) | 2008-09-11 | — | — | US | disclosed |
| WO-2008021924-A1 | PYRROLOTRIAZINE KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-02-21 | — | — | WO | disclosed |
| WO-2008018827-A1 | BENZIMIDAZOLE DERIVATIVES USEFUL IN TREATMENT OF VALLINOID RECEPTOR TRPV1 RELATED DISORDERS | ASTRAZENECA AB (SE) | 2008-02-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080221188-A1 | New Benzimidazole Derivatives | OPRD1, OPRK1, SDHA | TRPV1 10/4885GPR139 379/4885ENPP2 3316/4885 |
| US-20110137045-A1 | BENZIMIDAZOLE DERIVATIVES | OPRD1, OPRK1, SDHA | TRPV1 15/4885GPR139 682/4885ENPP2 3057/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.